SI2301576T1 - Terapevtska uporaba protiteles proti CS1 - Google Patents

Terapevtska uporaba protiteles proti CS1

Info

Publication number
SI2301576T1
SI2301576T1 SI200431948T SI200431948T SI2301576T1 SI 2301576 T1 SI2301576 T1 SI 2301576T1 SI 200431948 T SI200431948 T SI 200431948T SI 200431948 T SI200431948 T SI 200431948T SI 2301576 T1 SI2301576 T1 SI 2301576T1
Authority
SI
Slovenia
Prior art keywords
antibodies
therapeutic use
therapeutic
Prior art date
Application number
SI200431948T
Other languages
English (en)
Slovenian (sl)
Inventor
Marna Williams
J. Yun Tso
Nicolas F. Landolfi
Gao Liu
Original Assignee
Abbott Biotherapeutics Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en
Priority claimed from US10/982,357 external-priority patent/US7709610B2/en
Application filed by Abbott Biotherapeutics Corp. filed Critical Abbott Biotherapeutics Corp.
Publication of SI2301576T1 publication Critical patent/SI2301576T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SI200431948T 2004-03-29 2004-11-08 Terapevtska uporaba protiteles proti CS1 SI2301576T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55762204P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
US55762104P 2004-03-29 2004-03-29
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
EP10180748A EP2301576B1 (en) 2004-03-29 2004-11-08 Therapeutic use of Anti-CS1 Antibodies

Publications (1)

Publication Number Publication Date
SI2301576T1 true SI2301576T1 (sl) 2013-02-28

Family

ID=44597272

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431948T SI2301576T1 (sl) 2004-03-29 2004-11-08 Terapevtska uporaba protiteles proti CS1

Country Status (8)

Country Link
JP (1) JP4758984B2 (enExample)
CY (1) CY1115003T1 (enExample)
DK (1) DK2301576T3 (enExample)
ES (1) ES2393539T3 (enExample)
HR (1) HRP20120975T1 (enExample)
IL (1) IL243687A0 (enExample)
PT (1) PT2301576E (enExample)
SI (1) SI2301576T1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
EP3137498A1 (en) * 2014-05-02 2017-03-08 Cellectis Cs1 specific multi-chain chimeric antigen receptor
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046260A2 (en) * 1999-12-23 2001-06-28 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof

Also Published As

Publication number Publication date
PT2301576E (pt) 2012-12-20
JP2007530675A (ja) 2007-11-01
HRP20120975T1 (hr) 2013-01-31
JP4758984B2 (ja) 2011-08-31
IL243687A0 (en) 2016-04-21
CY1115003T1 (el) 2016-12-14
HK1099699A1 (en) 2007-08-24
ES2393539T3 (es) 2012-12-26
HK1155670A1 (en) 2012-05-25
DK2301576T3 (da) 2012-12-10

Similar Documents

Publication Publication Date Title
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
IL183458A0 (en) Anti-il-1r1 single domain antibodies and therapeutic uses
IL178593A (en) Specific antibodies of fcγriib and methods for their use
IL176958A0 (en) Compounds and methods of use
GB0419850D0 (en) Therapeutic agents
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
GB0416396D0 (en) Therapeutic agents
GB0403780D0 (en) Therapeutic agents
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
GB0419192D0 (en) Therapeutic agents
GB0423103D0 (en) Therapeutic agents
EP1740541A4 (en) THERAPEUTIC FORMULATIONS OF DESOXYEPOTHILONES
SI2301576T1 (sl) Terapevtska uporaba protiteles proti CS1
GB0417939D0 (en) Therapeutic agents
GB0400193D0 (en) Therapeutic agents
GB0400196D0 (en) Therapeutic agents
GB0427701D0 (en) Therapeutic agents
GB0416934D0 (en) Therapeutic agents
GB0428075D0 (en) Therapeutic agents
GB0402918D0 (en) Therapeutic agents
GB0403779D0 (en) Therapeutic agents
GB0421533D0 (en) Therapeutic use
GB0401256D0 (en) Production of human antibodies
GB0425532D0 (en) Therapeutic compounds and methods for their preparation and use